How I treat HIV-associated multicentric Castleman disease

Blood

Volumn 116, Issue 22, 2010, Pages 4415-4421

  Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; PLACEBO; PREDNISONE; RITUXIMAB; TOCILIZUMAB; VALGANCICLOVIR; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG RESPONSE; FEVER; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHADENOPATHY; LYMPHOMA; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SPLENOMEGALY;

EID: 78649480343     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-290213     Document Type: Review

References (70)

1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250(23):1001-1005.
2. Castleman B, Iverson L, Menendez V. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9:822-830.
3. Festen C, Flendrig JA, Schillings PH. [Giant lymphomas]. Ned Tijdschr Geneeskd. 1969;113(43): 1918-1919.
4. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996;105(3):268-276.
5. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406-1412.
6. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol. 2009;20(4):775-779.
7. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25-35.
8. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis. 1997;175(5):1198-1201.
9. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96(6):2069-2073.
10. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis. 2002;35(7):880-882.
11. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632-1634. (Pubitemid 38268952)
12. Loi S, Goldstein D, Clezy K, Milliken ST, Hoy J, Chipman M. Castleman's disease and HIV infection in Australia. HIV Med. 2004;5(3):157-162.
13. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32(7): 1006-1012.
14. Soulier J, Grollet L, Oskenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276-1280.
15. Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int. 2001;51(9):671-679.
16. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98(12):3473-3475.
17. Boivin G, Cote S, Cloutier N, Abed Y, Maguigad M, Routy JP. Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol. 2002;68(3): 399-403.
18. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103(11):4368-4369; author reply 4369.
19. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60(12):1350-1357.
20. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96(8):4546-4551.
21. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130-2136.
22. Judde JG, Lacoste V, Briere J, et al. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst. 2000;92(9): 729-736.
23. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25(22): 3350-3356.
24. Hillier JC, Shaw P, Miller RF, et al. Imaging features of multicentric Castleman's disease in HIV infection. Clin Radiol. 2004;59(7):596-601.
25. Guihot A, Couderc LJ, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur Respir J. 2005;26(1): 118-125.
26. Coca S, Salas I, Martinez R, Saez MA, Vaquero J. Meningeal Castleman's disease with multifocal involvement: a case report and review of literature. J Neurooncol. 2008;88(1):37-41.
27. Schmidt SM, Raible A, Kortum F, et al. Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia. 2008; 22(9):1782-1785.
28. Marcelin AG, Motol J, Guihot A, et al. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis. 2007;196(8): 1163-1166.
29. Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol. 2008;43(3):255-259.
30. Barker R, Kazmi F, Stebbing J, et al. FDGPET/ CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging. 2009;36(4):648-652.
31. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol. 1997;151(6):1517-1522.
32. Abe Y, Matsubara D, Gatanaga H, et al. Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease. Pathol Int. 2006;56(10):617-624.
33. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood. 2001;97(8):2526-2527.
34. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602-605.
35. Nishimoto N, Sasai M, Nakagawa M, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56-61.
36. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma. 2004;45(9):1939-1941.
37. Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood. 2009;113(19):4521-4524.
38. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009; 4(1):16-21.
39. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67.
40. Naresh KN, Trivedi P, Horncastle D, Bower M. CD20 expression in the HHV-8-infected lymphoid cells in multicentric Castleman disease. Histopathology. 2009;55(3):358-359.
41. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007; 147(12):836-839. (Pubitemid 351664423)
42. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease: long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2003;102(8):2786-2788.
43. Neuville S, Agbalika F, Rabian C, Briere J, Molina JM. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol. 2005;79(4):337-339.
44. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS. 2008; 22(13):1685-1687.
45. Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985;83(1):27-33.
46. Wynia MK, Shapiro B, Kuvin JT, Skolnik PR. Fatal Castleman's disease and pulmonary Kaposi's sarcoma in an HIV-seropositive woman. AIDS. 1995;9(7):814-816.
47. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol. 2001;66(2): 148-150.
48. Liberopoulos E, Tolis C, Bai M, Efremidis S, Pavlidis N, Elisaf M. Successful treatment of human immunodeficiency virus-related Castleman's disease: a case report and literature review. Oncology. 2003;65(2):182-186.
49. Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol. 2004; 75(3):176-177.
50. Bacon CM, Miller RF, Noursadeghi M, McNamara C, Du MQ, Dogan A. Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease. Br J Haematol. 2004; 127(5):585-591.
51. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol. 2006;76(3): 269-271.
52. Fowler A, Collins L, de Ruiter A, Whittaker S, Kulasegaram R, Bradbeer C. Multicentric Castleman's disease in a patient with HIV. Int J STD AIDS. 2006;17(1):63-64. (Pubitemid 43110460)
53. Casquero A, Barroso A, Fernandez Guerrero ML, Gorgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006;85(3):185-187.
54. Bouvresse S, Marcelin AG, Franck N, et al. The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. AIDS. 2007;21(11):1492-1494.
55. Izuchukwu IS, Tourbaf K, Mahoney MC. An unusual presentation of Castleman's disease: a case report. BMC Infect Dis. 2003;3(1):20.
56. Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol. 1995; 6(1):35-40.
57. Bestawros A, Michel R, Seguin C, Routy JP. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol. 2008; 83(6):508-511.
58. Dupin N, Krivine A, Calvez V, Gorin I, Franck N, Escande JP. No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient. AIDS. 1997; 11(11):1400-1401.
59. Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999;340(24):1923-1924.
60. Bottieau E, Colebunders R, Schroyens W, et al. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg. 2000;55(2):97-101.
61. Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008;9(6):336-388.
62. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol. 2005;17(5):447-455.
63. Senanayake S, Kelly J, Lloyd A, Waliuzzaman Z, Goldstein D, Rawlinson W. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol. 2003;71(3):399-403.
64. Revuelta MP, Nord JA. Successful treatment of multicentric Castleman's disease in a patient with human immunodeficiency virus infection. Clin Infect Dis. 1998;26(2):527.
65. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS. 2003;14(1):61-62.
66. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-2632. (Pubitemid 41510733)
67. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood. 2007;110(12):4132-4133. (Pubitemid 350248476)
68. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010. Blood. 2005;24:1538-1543.
69. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebocontrolled, crossover trial. J Infect Dis. 2008; 198(1):23-30.
70. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7): 2331-2336.